Nicolas Loebel - Ondine Biomedical CTO President
| OBI Stock | 12.50 0.50 4.17% |
President
Nicolas Loebel is CTO President of Ondine Biomedical
| Phone | 604 669 0555 |
| Web | https://ondinebio.com |
Ondine Biomedical Management Efficiency
The company has return on total asset (ROA) of (1.5971) % which means that it has lost $1.5971 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (6.8559) %, meaning that it generated substantial loss on money invested by shareholders. Ondine Biomedical's management efficiency ratios could be used to measure how well Ondine Biomedical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 4 records | PRESIDENT Age | ||
| Kevin Doyle | Molson Coors Beverage | N/A | |
| Frederic Landtmeters | Molson Coors Beverage | 50 | |
| Emelie Tirre | Monster Beverage Corp | 55 | |
| Guy Carling | Monster Beverage Corp | 48 | |
Management Performance
| Return On Equity | -6.86 | ||||
| Return On Asset | -1.6 |
Ondine Biomedical Leadership Team
Elected by the shareholders, the Ondine Biomedical's board of directors comprises two types of representatives: Ondine Biomedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ondine. The board's role is to monitor Ondine Biomedical's management team and ensure that shareholders' interests are well served. Ondine Biomedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ondine Biomedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nikita Parkhaev, Company Secretary | ||
| CFA CFA, CEO Founder | ||
| Elaine CPA, Corporate Controller | ||
| Vipul Shah, VP CFO | ||
| Simon Sinclair, Chief Director | ||
| Joseph Errico, Chief Officer | ||
| Mike Long, VP Operations | ||
| CIMA CPA, Interim Officer | ||
| Nicolas Loebel, CTO President | ||
| Thomas Dawson, Sr Devel | ||
| William Kanz, Senior Operations | ||
| Angelika Vance, Vice Communications | ||
| Matt Ross, Vice Marketing | ||
| Nikita Parkev, VP Secretary |
Ondine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ondine Biomedical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.86 | ||||
| Return On Asset | -1.6 | ||||
| Operating Margin | (9.12) % | ||||
| Current Valuation | 54.77 M | ||||
| Shares Outstanding | 442.04 M | ||||
| Shares Owned By Insiders | 42.85 % | ||||
| Shares Owned By Institutions | 21.00 % | ||||
| Price To Book | 5,236 X | ||||
| Price To Sales | 33.82 X | ||||
| Revenue | 1.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Ondine Stock
Ondine Biomedical financial ratios help investors to determine whether Ondine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ondine with respect to the benefits of owning Ondine Biomedical security.